A 50M + royalty all hinges on rota-cap sales. Can anyone comment on whether GSK are able to sell them for the Govt stockpile, given their temporary approval for the current pandemic ?
Without which, BTA should still earn roughly $36M from diskhaler sales.
Remember that last Qtr sales of relenza (all diskhaler) were soaked up by retail markets, especially Japan.
- Forums
- ASX - By Stock
- BTA
- roche first qtr tamiflu sales up 32%